中药复方藿莲香Ⅰ号的遗传毒理学研究

目的：根据前期藿莲香Ⅰ号药效学研究结果，进一步研究该复方的急性毒性和致突变作用，为其进一步应用的安全性提供理论依据。方法应用急性毒性实验、小鼠骨髓嗜多染红细胞微核试验、小鼠骨髓细胞染色体畸变试验和Ames试验检测该组分配伍复方的急性毒性和致突变性。结果急性经口毒性试验：雌性、雄性小鼠经口MTD均大于10g＆#183;kg-1，属实际无毒。致突变实验：小鼠骨髓嗜多染红细胞微核试验、小鼠骨髓细胞染色体畸变试验和Ames试验结果均为阴性，显示在本实验条件下，该中药复方未见有致突变性作用。结论中药复方藿莲香Ⅰ号未见有明显的急性毒性和致突变作用，表明该药物安全性良好。

Research on the Acute and Mutagenic Toxic Effect of Huolianxiang Compound

Objective To further evaluate acute toxicity and mutagenicity of Huolianxiang-I on the basis of previous pharmacodynamics results in order to provide theory basis for its further application. Methods The acute toxicity and mutagenecity of Huolianxiang-I were examined by acute oral toxicity test, mouse bone marrow polychromatic erythrocyte micronucleus test,mouse bone marrow chromosome aberration test and Ames test. Results For acute oral toxicity, maxi-mum tolerance doses of male and female mice are higher than 10g＆#183;kg-1 which are actually innocuity.For mutagenicity, negative results were seen in mouse bone marrow polychromatic erythrocyte micronucleus test,mouse bone marrow chromose aberration test and Ames test showing that Huolianxiang-I has no mutagenecity in this study. Conclusion No evident acute toxicity and mutagenicity are found in this study demonstrating that Chinese medicine compound Huo-lianxiang-I is safe.